FVIII forms amyloid aggregates in the ER that are dissolved in a chaperone-and glucosedependent manner to produce secreted active FVIII.
Introduction
Hemophilia A (HA), an X chromosome-linked bleeding disorder affecting ~10,000 males in the US, results from deficiency in coagulation FVIII, a component of the intrinsic blood clotting cascade 1, 2 . Presently HA is treated by protein replacement. Although, development of recombinant-derived FVIII significantly decreased risk of adventitious viral contamination, it greatly increased the cost of treatment, partially due to the low level of FVIII secretion from recombinant mammalian host cells 3 . FVIII is synthesized and translocated into the ER lumen where only properly folded proteins traffic to the Golgi compartment. The accumulation of unfolded/misfolded proteins in the ER activates the unfolded protein response (UPR), an adaptive signaling pathway evolved to resolve ER protein misfolding 4-6 . FVIII is susceptible to misfolding in the ER and was the first native endogenous protein shown to activate the UPR by binding to the ER protein chaperone BiP/GRP78 7, 8 . FVIII expression and an unresolved UPR leads to apoptosis 9 . A comprehensive understanding of the factors required for FVIII folding and secretion is unknown.
FVIII has the domain structure A1-A2-B-A3-C1-C2, where the B domain contains 18 potential N-linked glycosylation sites 1 . The A domains have amino acid homology to clotting factor V (FV) and ceruloplasmin, and structural homology to double barrel proteins, resembling the fold of cupredoxin domains 10, 11 . Energy depletion, with inhibitors of mitochondrial oxidative phosphorylation and glycolysis, selectively inhibits FVIII anterograde trafficking in the early secretory pathway 12, 13 , without affecting the trafficking of other proteins, including the homologous clotting factor V (FV) and von Willebrand factor (vWF), even within the same cell 12, 14 . A portion of FVIII traffics to the Golgi apparatus for processing by Furin to produce a heterodimer composed of an amino-terminal ~200kDa heavily glycosylated heavy chain (HC:
A1-A2-B) in complex with a carboxy-terminal ~80kDa light chain (LC: A3-C1-C2) linked through two copper ions in each of the A1 and A3 domains 15 that probably stabilize the A1 and A3 domains to promote A1-A3 interaction 16, 17 . Unfortunately, the molecular basis of FVIII folding and trafficking through the secretory pathway is poorly defined. Here we demonstrate that FVIII forms amyloid-like structures in the ER that can disaggregate, refold and be secreted as functional FVIII in mammalian cells. In addition, 1) a short amino acid motif, we termed Aggron, in FVIII is necessary and sufficient to seed aggregation; 2) glucose (Glc) metabolism is required to maintain FVIII solubility; and 3) two chaperone families, CANX/CRT and BiP, promote solubility, the latter is also required for FVIII disaggregation.
Methods

Reagents
All reagents are specified in Suppl. Information.
Standard Methods
Plasmid construction, cell lines and treatment with metabolic inhibitors 18 are detailed in Suppl.
Information. FVIII immuno-microscopy, activity and antigen measurement, pulse-chase & IP analyses 19 , co-IPs and Western blotting, sucrose gradient sedimentation 18 , membrane filtration 20 were standard and detailed in Suppl. Information.
Immunogold labeling TEM.
CHO-K1 or FVIII induced H9 cells were processed for immuno-gold localization of FVIII as in Suppl. Methods.
Negative stain TEM.
Lysates from CHO-K1 or H9 cells treated with SAHA were subjected to sucrose gradient sedimentation for FVIII IP, elution and analysis by TEM.
Transmission electron cryo-microscopy (cryo-EM).
IP'ed FVIII from sucrose gradient fractions of H9 cells was analyzed by cryo-EM as in Suppl.
Information.
Quantification and statistical analysis
All statistical analysis used Prism software 7. P values were calculated using one-way ANOVA. P < 0.05 was considered significant. Statistical significance in figures and legends is denoted by asterisks ( *** , p < 0.001; **** , p < 0.0001).
Results
FVIII forms amyloid-like aggregates in the ER.
Newly synthesized FVIII aggregates in the cell as monitored by sucrose gradient sedimentation 18 . Immunofluorescence (IF) microscopy was used to visualize steady state FVIII aggregation two different CHO cell clones. H9 cells express a low level of human FVIII that is inducible by histone deacetylase inhibitors (HDAC) [sodium butyrate (NaB) or suberoylanilidehydroxamic acid (SAHA)]. In H9 cells, Increased FVIII expression activates the UPR and apoptosis ( Fig. 1A) 8, 18 . 10A1 cells express high levels of FVIII constitutively without UPR activation 19 . FVIII in H9 and 10A1 cells displayed diffuse ER localization identified by colocalization with KDEL-containing ER proteins ( Fig. 1Bi; Fig. S1i ). NaB induction of FVIII synthesis in H9 cells increased FVIII staining that also co-localized with the KDEL ER marker ( Fig. 1Bii ). Treatment of 10A1 cells or H9 cells with 2'-deoxyglucose (2DG) and sodium azide (NaN 3 ) to inhibit Glc metabolism and oxidative phosphorylation, respectively, caused FVIII and KDEL proteins to co-localize to large perinuclear structures ( Fig. 1Biii ; Fig. S1i vs S1ii).
Thioflavin-S (Thio-S), upon selective binding to β-rich structures such as amyloid, increases fluorescence intensity 21, 22 . Intriguigingly, the metabolic poisons caused co-localization of Thio-S with FVIII, suggesting FVIII in the ER gained amyloid-like properties. Importantly, replacing the metabolic inhibitors with Glc-containing media for 4h, caused FVIII and KDEL proteins to resum their diffuse web-like ER co-localization and Thio-S co-staining was significantly reduced in both H9 and 10A1 cells ( Fig. 1Biv; Fig. S1iii ), suggesting at the histological level that FVIII aggregates disappear and traffic the secretory pathway.
FVIII aggregation was also analyzed by immuno-gold transmission electron microscopy (TEM). There was insignificant FVIII reactivity in controls not treated with primary antibody (Fig.   1Ci ), CHO cells that do not express FVIII ( Fig. 1Civ ) and modest reactivity in H9 cells that were not induced to express FVIII ( Fig. 1Cii ,v). Upon FVIII induction in H9 cells, FVIII was detected in clusters detected by two independent FVIII antibodies coupled to 12nm gold particles ( Fig.   1Ciii ,vi). In addition, immunolocalization of PDIA6 by secondary antibody conjugated to 18nm gold particles demonstrated co-localization of FVIII and an ER resident protein (Fig. 1Ciii ,vi and expanded on right).
The structure of purified FVIII aggregates in NaB-treated H9 cells was analyzed by conventional TEM and transmission electron cryo-microscopy (cryo-EM). After FVIII induction, cell lysates were sedimented on sucrose gradients 18 . FVIII was immunoprecipitated (IP'ed) from each fraction, eluted from the beads and analyzed by TEM and cryo-EM. Fibrils of approximately ~5nm diameter were visible in negatively stained TEM images from the heavy molecular weight (HMW) fractions (white arrows, Fig. 1D ) from NaB-treated H9 cells, likely representing aggregated FVIII. These fibrils were absent in the light fractions, presumably containing monomeric FVIII (not shown). Cryo-EM images of FVIII IP'ed from HMW fractions displayed dense networks of fibrils with diameters of 5.1±0.5nm. The fibrils appeared to interact with each other in various ways and form amyloid-like aggregates reminiscent of Poly-Q aggregates observed by cryo-EM in mammalian cells 23 (Fig. 1E ). Antibody gold labeling for FVIII further confirmed that these fibrils are composed of FVIII. Importantly, no fibrils were detected in fractions similarly prepared from CHO cells that do not express FVIII (not shown). Therefore, FVIII forms fibrils which are morphologically similar to those reported for other amyloidogenic proteins 24 .
Aggregated FVIII disassembles and refolds into secreted functional protein.
Energy depletion, with inhibitors of mitochondrial oxidative phosphorylation and glycolysis, causes FVIII aggregation and selectively inhibits FVIII trafficking to the Golgi 12, 14 .
Analysis of FVIII aggregation by sucrose gradient fractionation is time consuming and does not allow easy comparison between multiple variables. To examine the fate of FVIII in cells upon bioenergetic collapse and recovery we performed pulse-chase radiolabeling and IP for SDS-PAGE and autoradiography 19 , and the same samples were analyzed by a cellulose acetate (CA)
filter-binding assay 20 which retains amyloid aggregates for analysis of FVIII aggregation in a more reproducible, robust, and convenient manner. Cells were pulse-radiolabeled, treated with or without 2DG and NaN 3 for 2h and subsequently recovered in Glc-containing medium for up to 4h for harvest of cell lysates and conditioned media. Membrane filtration and detection with FVIII antibody demonstrated immediately after treatment with 2DG and NaN 3 , which decreased cellular ATP by 5-fold ( Fig. S2A,B ), increased FVIII retention on CA that subsequently declined upon Glc recovery ( but also functional FVIII activity in the medium (Fig. 2Aiii ). Adding CHX during the chase recovery reduced the FVIII activity in the medium by ~50% (Fig. 2Aiii , lane 9), indicating that ~half of the FVIII activity was previously synthesized and was likely derived from aggregated FVIII. In addition, the decline in aggregated FVIII was not due to proteasomal or autophagic degradation ( Fig. S2C ). These findings support the notion that FVIII intracellular aggregates were dissolved and refolded for secretion of active FVIII.
Glucose metabolism promotes FVIII solubility.
We then tested whether glycolysis and/or oxidative phosphorylation is required to prevent FVIII aggregation using specific inhibitors. Inhibition of Glc metabolism by 2DG
immediately induced FVIII aggregation, where inhibition of oxidative phosphorylation had no effect ( Fig. 2B, Fig. S2D ) indicating that Glc metabolism is required to solubilize FVIII. The role of Glc metabolism in reducing FVIII aggregates is under investigation. We next tested whether FVIII aggregation involves hydrophobic interactions. The FVIII aggregates in cell lysates were solubilized with 1%SDS prior to CA filtration ( Fig. 2C) , although a long exposure demonstrated that ~3% of the FVIII aggregates were resistant to 1%SDS.
A sheet within the FVIII A1 domain is necessary and sufficient for FVIII aggregation.
Mutation of Phe309 in FVIII to Ser, the homologous residue in FV (Fig. 3A) , conferred the efficient secretion of FV onto FVIII 13 . To test whether this region predisposes to aggregation, we analyzed mutants that increase (F309S; ES) or decrease [7LF-A(7 mutations of L and F to A); F306W] FVIII secretion by CA membrane retention. Expression of mutants VES and TES was reduced, thus limiting interpretation. Mutations that increased FVIII secretion (F309S and ES) reduced aggregation and those that reduced secretion increased aggregation ( Fig. 3B ,C), indicating this region might predispose to aggregation.
To test whether residues in the FVIII A1 domain are sufficient to promote aggregation, we introduced 79 residues (aa253-331) in frame into the enhanced green fluorescent protein Application of the TANGO algorithm, which predicts cross -sheet propensity 25 , to the 79aa identified two regions that can form -sheets ( Fig. S4 ). Although C310S substitution did not alter the TANGO plot, F309S or C310E substitutions or the respective 79aa from FV eliminated the second -sheet at F309. In contrast, F306W substitution, which further reduces secretion, enhanced the peak at F309. We tested the significance of these residues by expressing F309S and C310E mutations for analysis of aggregation by sucrose gradient sedimentation ( Fig. 3G,H) . In contrast to eGFP-CMy without FVIII sequence which migrated in light fractions 2-4, the majority of wtFVIII-eGFP-CMy migrated in heavy fractions 5-10. In contrast for both F309S and C310E, ~10% of the FVIII-eGFP-CMy sedimented in fraction 3.
Thus, these results support the validity of the TANGO analysis and show both F309 and C310 significantly contribute to FVIII aggregation.
The aggregation properties of the 79aa was further analyzed by removing eGFP to study wt and F309S FVIII-CMy in context of a smaller peptide ( Fig. 4A ). For controls, CMy was expressed alone or with insertions of eGFP (eGFP-CMy) or the homologous residues from FV (FV-CMy). These polypeptides were detected in transfected 293T cells by Western blotting (Fig.   S3B ). Cpep ELISA revealed wtFVIII-CMy was poorly secreted, where FV-CMy and F309SFVIII-CMy secretion was ~5 to ~10-fold greater (Fig. 4B ). However, secretion of the unrelated controls CMy or GFP-CMy was significantly further increased. Inversely correlating with secretion, wtFVIII-CMy was aggregated upon CA filtration, whereas F309SFVIII-CMy aggregation was reduced to 60% ( Fig. 4C ). Aggregation of eGFP-CMy and FV-CMy was not detectable ( Fig. 4F ). Sucrose gradient sedimentation also demonstrated reduced aggregation for F309S FVIII-CMy ( Fig. 4D and Fig. S5 ). We next tested whether the wtFVIII-CMy aggregates have properties similar to full-length wtFVIII aggregates. Sucrose gradient fractions #3 and #10 from wtFVIII-CMy expressing 293T cells were challenged with 1%SDS, 10mM DTT or -ME prior to CA filtration. Similar to wtFVIII in H9 cells, these aggregates were sensitive to 1%SDS but resistant to DTT and -ME ( Fig. 4E , and data not shown). Together, these findings confirm that the 79aa initiate aggregation of structures that appear biochemically similar to wtFVIII.
Since Glc addition to 2DG-treated H9 cells solubilized wtFVIII aggregates, we tested whether 2DG causes the short wtFVIII-CMy chimera to aggregate. Indeed, 2DG and NaN 3 treatment increased wtFVIII-CMy aggregation monitored by CA filtration, with only a slight reduction in expression ( Fig. 4F and Fig. S3B ). These metabolic inhibitors did not significantly cause aggregation of CMy, FV-CMy or eGFP-CMy. In addition, recovery in Glc decreased wtFVIII-CMy aggregation ~50% (Fig. 4F ), consistent with observations of wtFVIII in H9 and 10A1 cells. This suggests that FVIII aggregation was not simply a consequence of altered glycosylation in response to 2DG because wtFVIII-CMy contains no N-linked glycans.
Finally, the potential of wtFVIII-CMy to form intermolecular heterodimers/oligomers with FVIII was investigated. wtFVIII-CMy and full-length wtFVIII or B domain-deleted FVIII (BDD), which aggregates similar to wtFVIII (not shown), were co-expressed in 293T cells, and their interaction was analyzed by co-IP. Surprisingly, Cpep IP of the short chimera wtFVIII-CMy efficiently pulled-down both wtFVIII and BDD (Fig. 4Gi , ii), suggesting that these 79aa interact in trans to alter the wtFVIII folding pathway.
BiP and CANX/CRT prevent FVIII aggregation in the ER.
Mass spectrometry of FVIII IP'ed from control CHO cells and H9 cells treated with NaB identified many ER chaperones and enzymes that selectively interact with wtFVIII ( Fig. S6A,B ).
FVIII interactions with BiP, CANX, UGGT1, SEL1L and PDIA6 were validated by FVIII IP and
Western blotting ( Fig. S6C ). PDIA6 also co-localized with FVIII by immuno-gold TEM ( Fig. 2A ).
The two most significant FVIII interactors were BiP/HSPA5 and its co-chaperones (ERdj5, ERdj3, and GRP170) and CANX/CRT with its associated factors UGGT1 and ERP57/PDIA3, raising question whether these chaperones influence FVIII aggregation.
Complete inhibition of the CANX/CRT cycle with castanospermine (CST), an inhibitor of αglucosidase (GS1 and GS2) activity, increased FVIII aggregation without altering FVIII expression ( Fig. S7A-C ), suggesting that CANX/CRT prevents wtFVIII aggregation, possibly by binding soluble mono-glucosylated N-linked glycans on FVIII. However, CST treatment of cells expressing the wtFVIII-CMy short chimera did not significantly increase wtFVIII-CMy aggregation ( Fig. S7D ,E), confirming that aggregation of the 79aa is not due to altered glycosylation because this chimera has no N-glycans.
To study the role of BiP in FVIII aggregation, we analyzed whether BiP binds to LMW and/or HMW wtFVIII species. Cell lysates from NaB-treated H9 cells were analyzed before ( Fig.   5Ai ) and after sucrose gradient sedimentation ( Fig. 5Aii ) by FVIII IP and Western blotting.
Although similar amounts of wtFVIII migrated in LMW fractions 5 (L) from both untreated and NaB-treated H9 cells (Fig. 5Aii, lanes 1,3) , there was a vast amount of FVIII in the HMW fraction 10 (H) (Fig. 5Aii , lane 2), with even more upon NaB induction (Fig. 5Aii , lane 4). FVIII IPs analyzed by Western blotting demonstrated detectable BiP interaction only with the LMW fraction of FVIII from NaB-treated, and not in untreated H9 cells ( Fig. 5Aii, lanes1 ,3). BiP was not detected in the HMW fraction ( Fig. 5ii, lanes 2,4) , nor did we detect BiP in the post-IP HMW sucrose fraction supernatant (Fig. 5Aii, lanes 6, 8) . Significantly, the majority of BiP was detected in the FVIII post-IP supernatant in the LMW fraction ( Fig. 5Aii, lanes 5,7) , suggesting that BiP preferentially associates with LMW FVIII.
To further analyze how BiP impacts FVIII aggregation, we used the Shiga-toxic E. coli virulence factor SubAB that specifically and acutely cleaves at a single site in the hydrophobic linker that connects the BiP N-terminal ATPase domain with the substrate binding domain (Fig.   5B ) 26, 27 . As control, cells were treated with a protease mutant (SubA 272 B mt ). Treatment of cells with 1 or 2 g/ml of the active protease acutely cleaved ~35% and ~85% of BiP, respectively, and increased FVIII aggregation detected by retention on CA membranes (Fig. 5C ), suggesting that intact BiP, but not cleaved BiP, prevents FVIII aggregation. BiP cleavage was associated with UPR activation by induction of P-eIF2 and CHOP (Fig. 5C ), consistent with previous findings 28 .
Although the above findings indicate that BiP and CANX/CRT prevent FVIII aggregation, they do not address their role in disaggregation. Hence, we treated H9 cells with NaB for 18h with the last 2h in the presence of 2DG and NaN 3 to induce maximal FVIII aggregation. Then, fresh media with Glc was added for 4h in the presence or absence of SubAB protease or CST.
Although 2DG and NaN 3 reduced FVIII expression, BiP cleavage prevented the Glc-dependent dissociation of FVIII aggregates (Fig. 5D ). In contrast, inactivation of the CANX/CRT cycle by CST did not significantly prevent disaggregation. Collectively, we conclude that BiP, and not CANX/CRT, is required to disaggregate polymerized FVIII.
To evaluate the role of BiP in preventing FVIII aggregation, BDD-FVIII, which exhibits similar aggregation properties as wtFVIII, was co-expressed with Flag-tagged BiP (BiP-F), mutant V461FBiP-Flag (BiPmt-F), which is peptide-binding defective 29 , or Myc-tagged BiP (BiP-M) 29 . Forced expression of BiP-F or BiP-M did not alter BDD-FVIII expression, although they significantly reduced BDD-FVIII aggregation (Fig. S8 ). In addition, the V461F mutant BiP was partially defective in preventing BDD-FVIII aggregation. Thus, we conclude that BiP requires its peptide binding site to efficiently promote FVIII solubility in the ER.
We next tested whether BiP cleavage by SubAB impacts aggregation of the wtFVIII-CMy chimera. 293T cells expressing wtFVIII-CMy were treated with mt or wtSubAB. At 2.5h after SubAB protease addition, ~40-50% BiP was cleaved without affecting wtFVIII-CMy expression ( Fig. 5E, top) . Compared to mtSubAB treatment control, wtFVIII-CMy aggregation increased ~60% upon BiP cleavage (Fig. 5E, bottom) . Although SubAB inhibits secretion of immunoglobulin 30 , secretion of eGFP-CMy was not reduced (Fig. S9A,B ), indicating the secretory pathway remained intact. Collectively, these findings show that intact BiP prevents aggregation of wtFVIII-CMy through interaction with the BiP peptide binding site.
BiP interacts with wtFVIII-CMy to prevent aggregation.
We tested whether binds to the 79aa by co-expression of wtFVIII-CMy with BiP-F or the peptide-binding defective BiPmt-F 29 . Indeed, Flag IP of BiP co-IP'ed wtFVIII-CMy ( Fig. 5F ), suggesting a direct interaction between BiP and the 79aa of FVIII. In contrast, wtFVIII-CMy did not co-IP with mutant BiPmt-F. However, treatment with 2DG and NaN 3 did not significantly increase the BiP-wtFVIII-CMy interaction, consistent with the notion that SubAB toxin cleavage of BiP induces wtFVIII-CMy aggregation, as we could not detect BiP binding to HMW FVIII aggregates ( Fig. 5A ). However, mutations that reduce FVIII-CMy aggregation did not detectably alter BiP interaction measured by co-IP (not shown). It is likely that BiP binds multiple sequences so mutations that reduce aggregation do not alter BiP interaction, as previously suggested 31, 32 . These findings support the conclusion that BiP binds 79aa in wtFVIII-CMy to prevent aggregation.
Discussion
FVIII forms reversible amyloid-like aggregates in the ER.
FVIII is poorly secreted due to retention in the ER. Here we provide significant insight into the mechanism for FVIII retention in the ER. We demonstrated that FVIII forms amyloid-like structures in the ER when expressed constitutively and to a greater extent upon increased synthesis. In addition, inhibition of Glc metabolism, but not oxidative phosphorylation, causes 
BiP and CANX/CRT prevent FVIII aggregation.
Mass Spectrometry demonstrated FVIII interaction with BiP and CANX/CRT. Here, we
show CANX/CRT interaction reduces wtFVIII aggregation, similar to other glycoproteins 34, 35 . BiP preferentially binds to LMW FVIII and not HMW FVIII aggregates. BiP inactivation increased FVIII aggregation and forced BiP expression reduced FVIII aggregation. Thus, BiP is required to prevent FVIII aggregation and/or to mediate disaggregation. It was shown that increased BiP expression inhibits wtFVIII secretion 14 . However, contrary to what we expected, increased BiP expression prevented wtFVIII aggregation and retained soluble LMW FVIII in the ER. From these findings, we propose a model for BiP function in preventing FVIII aggregation (Fig. 6) .
Identification of the -aggregate seeding region in the FVIII A1 domain.
To further characterize FVIII aggregation, we identified 79aa in the A1 domain that seed -aggregation. Expression of a chimeric polypeptide (wtFVIII-eGFP-CMy or wtFVIII-CMy) recapitulated the major aspects of wtFVIII aggregation including: i. wtFVIII-CMy aggregated in response to glycolysis inhibition; and ii. wtFVIII-CMy aggregated in response to BiP cleavage by SubAB cytotoxin. In addition, we show that the 79aa motif interacts in trans with wtFVIII and BDD-FVIII as well as with the peptide binding site on BiP. We propose BiP binding to the FVIII aggregate seeding region, Aggron, prevents aggregation, consistent with previous reports of other proteins 31, 36, 37 . As BiP prevents FVIII aggregation, it is interesting to note that three BiP cochaperones ERdj3, ERdj5, and GRP170, the latter two which interact with aggregation prone sequences 31 , were also identified as significant interactors with wtFVIII. Although previous studies linked co-chaperone interactions with ER-associated degradation (ERAD), FVIII is not significantly degraded by ERAD, but rather is secreted. Present studies are testing the significance of these co-chaperone interactions. Importantly, without the complication from glycosylation sites and disulfide bonds, wtFVIII-CMy did not aggregate upon inhibition of the CANX/CRT cycle, implicating the glycans important for solubility. Finally, these observations of FVIII aggregation were cell-type independent as they were observed in CHO, 293T, COS-1 as well as hepatocytes in vivo (not shown).
Can FVIII aggregation impact human HA gene therapy?
At least three HA gene therapy clinical trials are in progress delivering BDD-FVIII in adeno-associated viral vectors to hepatocytes (https://clinicaltrials.gov/ct2/results?term =hemophilia+a+gene+therapy). One report demonstrated significant success in 9 men with severe HA at 1 year after virus delivery to obtain 100% FVIII levels in the blood 38 . However, a more recent update indicated the FVIII levels in the high dose cohort (6e 13 vector genomes/kg) decreased ~50% after year 2 39 , which is unusual compared to the stable expression observed in other hepatocyte-directed AAV gene therapy trials 40, 41 . All the properties of wtFVIII misfolding and aggregation also exist for the BDD-FVIII that is used in the present gene therapy clinical studies 9 . It should be considered that the decline in FVIII expression may reflect toxicity of aggregated BDD-FVIII in hepatocytes. In addition, endogenous FVIII is not likely expressed in hepatocytes, but rather in Kupffer cells and sinusoidal endothelial cells [42] [43] [44] which may harbor machinery to efficiently fold FVIII. We also observed aggregation of BDD-FVIII in hepatocytes of mice that received BDD-FVIII DNA expression vectors, that was not observed for F309SFVIII ( 9 and data not shown). Recently, it was shown that ER protein misfolding in hepatocytes with subsequent inflammation caused by a high fat diet in mice can initiate non-alcoholic fatty liver disease (NAFLD) with progression to non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma 45 . Thus, it will be important to monitor liver function in the HA gene therapy studies.
Importantly, why does FVIII harbor an Aggron in the A1 domain? Intriguingly, the Aggron includes Cys310 which ligands Cu + in functional wtFVIII 15 . Of all single amino acid variants that reduce FVIII aggregation and improve secretion, F309S was the most effective.
Previously, it was demonstrated that F309SFVIII exhibits clotting factor specific activity, thermal denaturation and thrombin activation indistinguishable from wtFVIII 13 . However, F309S FVIII was 10-fold more sensitive to EDTA inactivation, which presumably extracts Cu + . Thus, we propose this Aggron produces an anti-parallel -sheet hairpin between the 7 th and 8 th sheets in the double barrel that stabilizes the C310-Cu + interaction. Because F309SFVIII and F309S
BDD-FVIII are functionally identical to wtFVIII and BDD-FVIII, respectively, do not aggregate or activate the UPR and are secreted efficiently, they should be considered a safe alternative to wtFVIII or BDD-FVIII for HA gene therapy. 
